Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193541 · ClinicalTrials.gov registry record
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 900
- Enrollment target
- 8
- Study locations
NCT03193541: Recruiting study of Bladder Cancer, sponsored by Cedars-Sinai Medical Center.
NCT03193541 is a study of Bladder Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 900 participants, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03193541, a study of Bladder Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 8
- Study locations
Study Summary
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Conditions Studied
Study Locations (8)
California
- VA Long Beach Healthcare System - Long Beach
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Medical Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
New York
- University of Rochester Medical Center - Rochester
Texas
- UT Southwestern Medical Center at Dallas - Dallas
Nara
- Nara Prefecture Seiwa Medical Center - Nara
Other
- Nara Medical University - Nara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2029-02 |
What NCT03193541 shows while recruiting
NCT03193541 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03193541 lists 8 locations in 5 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT03193541 about?
NCT03193541 is a clinical study titled "A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer". To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
What is the current status of trial NCT03193541?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2016-12-30. Estimated completion is 2029-02.
What conditions does trial NCT03193541 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT03193541?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03193541 being conducted?
This trial has 8 study locations across California, New York, Texas, Nara. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03193541's enrollment target sits among peer trials
900 20th of 175 higher than 156 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI